TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04077476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Yoga + Facebook
Description: Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Yoga
Description: Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
Study: NCT04036643

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
Study: NCT04252833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-044
Description: CT-044 HCl is a reactive species decomposition accelerant
Study: NCT01536275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition
Description: Withholding parenteral nutrition during the first 7 days of ICU stay
Study: NCT02088515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT03917433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Exposure Therapy
Description: Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile Feedback
Description: In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile Feedback
Description: In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Point-based Rewards
Description: Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Point-based Rewards
Description: Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
Study: NCT04644783

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test assay
Description: Participants will have their blood drawn and be evaluated with a new blood assay that screens a large number of foods (more than 20) in a culture plate. Participants will be asked to eat the identified safe foods by the the blood assay.
Study: NCT04110600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coffee effect on early gastric motility
Description: this group 100ml coffee after two hours
Study: NCT03391869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Undergo radiation and/or surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT04110600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy pepper mint oil on motility
Description: This group 100me pepper mint oil after 2 hours
Study: NCT04972747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin care with sunflower oil
Description: The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin care with sunflower oil
Description: The application will be carried out twice a day during the maintenance hours of the service. In skin care applications, body baths are applied not more than three times a week, as it may cause hypothermia in preterm babies in the ward routine. In daily skin care, body cleaning with cotton, changing the fixation points such as orogastric probe, and changing the monitor probe locations are among the routine practices. In order to hydrate and moisturize the skin in preterm and term babies, baby oil in the service is used. Skin care applied in the service routine will be applied to the preterm babies included in the study, and only sunflower oil and coconut oil will be used as moisturizers.
Study: NCT01363414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate
Description: one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: one drop of sterile 0.9% sodium chloride solution in the other eye
Study: NCT03221764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone with CoSeal
Description: CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients \[8\]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 driver
Description: The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
Study: NCT03969992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroFact
Description: Aerosolized SF-RI 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroFact
Description: Aerosolized SF-RI 1

Intervention type: OTHER
Group type: OTHER
Intervention: nCPAP
Description: nCPAP (nasal continuous positive airway pressure) alone
Study: NCT02793128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-101 instillations
Description: Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
Study: NCT04958915

Intervention type: DIAGNOSTIC_TEST
Intervention: Knee joint 30° flexion scan
Description: The patient was placed in the supine position, and the knee joint was naturally placed in the knee joint special coil, and the knee joint 30° flexion position scan.
Study: NCT03921879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-82 Dose Escalation
Description: The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-82 Dose Expansion
Description: A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
Study: NCT02775851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT03769168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
Study: NCT04150133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Residue Diet
Description: Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Residue Diet
Description: Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
Study: NCT00881751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT01988376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surepath
Description: A liquid-base method of Pap smear for screening the recurrence of cervical cancer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Pap smear
Description: Conventional Pap smear
Study: NCT02258074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanthanum Carbonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Nicotinamide)
Description: Sugar pill manufactured to mimic Nicotinamide 750 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Nicotinamide)
Description: Sugar pill manufactured to mimic Nicotinamide 750 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for lanthanum carbonate)
Description: Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for lanthanum carbonate)
Description: Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
Study: NCT01814904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan-L
Description: body surface area equivalent (BSAeq) 3 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan-M
Description: BSAeq 6 g/day
Study: NCT00378079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling Only
Description: Counseling only in prison, with passive referral to drug abuse treatment upon release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Counseling + Transfer
Description: Counseling only in prison, with opportunity to enter methadone maintenance upon release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Counseling + Methadone
Description: Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
Study: NCT00546221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support exercise programme
Description: The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed exercise
Description: This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
Study: NCT03348397

Intervention type: PROCEDURE
Intervention: right ventricular outflow tract reconstruction with contegra
Description: Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.

Intervention type: PROCEDURE
Intervention: right ventricular outflow tract reconstruction with pulmonary homograft
Description: cryopreserved pulmonary homografts
Study: NCT00620035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiopaque Etonogestrel Implant
Description: One implant inserted for a 3-year treatment period
Study: NCT03434509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Tai Chi and Mindful Movement classes
Description: Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing).
Study: NCT04331171

Intervention type: DEVICE
Intervention: Web application users
Description: questionnaire of comorbidity and symptoms completed by the patient on his smartphone
Study: NCT01642121

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02510755

Intervention type: OTHER
Group type: OTHER
Intervention: MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Study: NCT04537221

Intervention type: BIOLOGICAL
Intervention: Blood transfusion
Description: Transfusion of red blood cells peri-operatively

Intervention type: BIOLOGICAL
Intervention: Blood transfusion
Description: Transfusion of red blood cells peri-operatively
Study: NCT00805233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination ranibizumab + bromfenac
Description: ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
Study: NCT04475848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
Study: NCT04531072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
Study: NCT02379897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Study: NCT00805233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab injection alone
Description: ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
Study: NCT03318419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 5mg/㎡ d1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300ug d0-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10mg/㎡ q12h SC d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500U/m2 im d1
Study: NCT02264041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilobradine, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilobradine, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilobradine, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT02392715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with Threshold by respironics
Description: Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Inspiratory muscle training
Description: with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)
Study: NCT01814904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan-H
Description: BSAeq 9 g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBPB
Study: NCT01321567

Intervention type: DRUG
Intervention: rabeprazole sodium
Description: Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.